News

News 07.07.2021 Zurich-Schlieren, Switzerland, July 7, 2021. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that the group of Prof. J Morote Robles from the Vall d’Hebron University Hospital in Barcelona, Spain will present their clinical study results of Proclarix® in combination with MRI for improved prostate...

Events, External events
Event date: 07.09.2021   Registration:  https://swissbiotechday.ch/registration/

News 22.06.2021 Schlieren (Zurich), Switzerland, 22, 2021 – Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron...

News 16.06.2021 Zurich-Schlieren, Switzerland, June 16, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") at a public offering price...

News 14.06.2021 Zurich-Schlieren, Switzerland, June 13, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of...